Six integrated Manufacturing and Supply units with end-to-end responsibility for manufacturing, internal & external supply.
Large Molecules Platform
The Large Molecules Platform is based on synergies and interlinks between the Biotech Drug Substance sites (comprising management of cell banks, upstream and downstream processes) and Drug Product sites (that include formulation, filling under aseptic conditions and packaging).
Cell & Gene Therapy Platform
The Cell and Gene Therapy Platform mission is to collaboratively deliver timely access to cost-effective, quality, innovative medicines which improve and extend patient lives. The platform is responsible for the manufacturing of ground-breaking cell and gene therapies, including Chimeric Antigen Receptor T-Cell (CAR-T) therapy. This CAR-T therapy is tailored individually to and manufactured for each patient via pioneering technology. Currently the platform consists of three internal CAR-T manufacturing sites and four CMOs.
Small Molecules Platform
This platform aims to optimize and further enhance the end-to-end supply of small molecules innovative medicines products to become a top-class customer service center and reliable partner to our customers and patients.
Sandoz Technical Operations Platform
The platform has full end-to-end responsibility for all dedicated Sandoz production sites, Sandoz external suppliers and the end-to-end Sandoz Supply Chain. TechOps Strategy, network decisions, Capex allocation, supply point decisions and volume strategy (including CMO/B2B) are fully owned by this team and are developed and executed in full alignment with the Sandoz Divisional Strategy.
Ophthalmology and Local Market Manufacturing
The Ophthalmology and Local Market Manufacturing (LMM) Platform's mission is to create, maintain and/or leverage patient & market access by driving focused ophthalmology business and creating local competitive advantages through Technical Operations value creation and innovation, by delivering affordable medicines to patients and becoming more agile.
Novartis Gene Therapies
The mission of Novartis Gene Therapies (GTx) is to become the global leader in gene therapy. From the lab to the patient, and every stop along the way, GTx is relentless in its dedication to developing and commercializing transformational gene therapies. Gene therapy stands at the very forefront of scientific advancement and is helping to usher in both a new way of treating genetic diseases and new futures for patients impacted by them.
Note: Contract Manufacturing - In addition to the above platforms, we recently launched Global Biotech Corporations. This new unit will focus on producing biologics and cell and gene products for other companies, leveraging our outstanding manufacturing assets, technology, and capabilities from different parts of our organization, and our highly skilled teams.
In Quality, our guiding purpose is to have a positive impact on patients. With a goal to go beyond compliance and look to serve our patients effectively, we are transforming to become an agile quality organization by –
- simplifying our operations for efficiency
- eliminating duplication and
- innovating how we work
to focus on what really matters, making and supplying life-changing medicines to our patients.
3 years, 4 sites, 3 production platforms. Having started as a trainee, I have since moved into a position which is central to our production organization where I am able to improve and stabilize processes by working closely with colleagues across different functions.
Julian, Process Expert